September 1, 2020
Daiichi Sankyo said on August 31 that its anticoagulant edoxaban met the primary endpoint in a Japan PIII study in elderly patients with non-valvular atrial fibrillation and high bleeding risks. The ELDERCARE AF Study was designed to look into the...read more